ArticlePloS one2025
Identification of shared key genes in Rheumatoid Arthritis and COVID-19 and their relevance as diagnostic biomarkers and with immune infiltration: New insights from bioinformatics analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction mechanism between Coronavirus Disease (COVID-19) and rheumatoid arthritis (RA) remains inadequately understood. Consequently, this study sought to elucidate the potential mechanisms underlying the comorbidity between RA and COVID-19, as well as to identify key genes, diagnostic markers, and associated immune cells. Differential analysis of the training set, derived from the GEO database, identified differentially expressed genes (DEGs) in the RA and COVID-19 gene chip and sequencing datasets. Weighted Gene Co-expression Network Analysis (WGCNA) identified key modular genes, while protein-protein interaction (PPI) network analysis revealed hub genes, which were validated by the validation set. Receiver Operating Characteristic (ROC) curves were used to assess clinical relevance. Cytoscape-based transcription factor (TF)-mRNA and microRNA (miRNA)-mRNA regulatory networks were used to identify potential therapeutic targets, and immune cell infiltration was evaluated using the CIBERSORT algorithm. Differential expression analysis identified 2,778 DEGs in RA and 12,733 in COVID-19, with WGCNA identifying 18 shared genes, suggesting possible common molecular mechanisms. Validation analysis confirmed LGMN and NRGN as key genes associated with RA and COVID-19 comorbidity, highlighting their diagnostic significance. Network analysis identified related miRNAs and TFs, and enrichment analysis revealed the critical signaling pathways. Immune cell infiltration in patients with RA and COVID-19 was assessed using the CIBERSORT algorithm. This study preliminarily explored the shared pathogenic mechanisms between RA and COVID-19, identifying LGMN and NRGN as potential biomarkers for both diseases. Notably, NRGN may play a significant role as a common biomarker involved in the immune response in both disease states. These findings may open new avenues for the diagnosis and treatment of RA and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.